Evaluation of the relationship between serum levels of total antioxidants and vitamin D supplementation in hemodialysis patients

Abstract

Oxidative stress, as an essential part of chronic kidney disease, is associated with morbidity and mortality in hemodialysis (HD) patients. Moreover, in these patients, deficiency ⁄ insufficiency of vitamin D (25-OH-D levels less than 30 ng⁄ml) is extremely common signifying that HD patients have two vitamin D-related problems and require different treatment regimens. It was the aim of this study to evaluate the impact of cholecalciferol (vitamin D3) supplementation in HD patients with hypovitaminosis D. Methods. Eighty-six hemodialysis patients with hypovitaminosis D were enrolled in a single-center, parallel-arm, randomized, double-blind, placebo-controlled trial. The patients were randomized into two groups (n= 44 and 45) to receive 50,000 IU of cholecalciferol or placebo every week for 12 weeks. Serum levels of total antioxidant capacity (TAC), malondialdehyde (MDA), serum 25‐hydroxyvitamin D (25(OH)D), klotho and FGF23 were compared between the groups. Results. Cholecalciferol supplementation significantly increased the serum 25OH(D) levels when compared to placebo (p = 0.006). It was not accompanied by changes in the levels of MDA, TAC, phosphate, total and ionized calcium, and parathyroid hormone in the intervention group compared to basic status.